decibel therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. hearing loss is the most prevalent form of sensory impairment. it is estimated that 50 million people in the u.s., and 360 million people worldwide, suffer from some type of hearing loss. hearing disorders affect people of all ages and can have a profound impact on quality of life. by combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. founded by the world’s preeminent experts in inner ear biology and hearing disorders, decibel therapeutics was launched in 2015 by third rock ventures and sr one and is headquartered in boston, mass. for more inf
Company profile
Ticker
DBTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
464198709
DBTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Oct 23
EFFECT
Notice of effectiveness
6 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Sep 23
POS AM
Prospectus update (post-effective amendment)
25 Sep 23
8-K
Completion of Acquisition or Disposition of Assets
25 Sep 23
SC 14D9/A
Tender offer solicitation (amended)
25 Sep 23
25-NSE
Exchange delisting
25 Sep 23
SC TO-T/A
Third party tender offer statement (amended)
25 Sep 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13D/A
REGENERON PHARMACEUTICALS, INC.
27 Sep 23
4
Anna Trask
25 Sep 23
4
William H. Carson
25 Sep 23
4
John Jui-Jen Lee
25 Sep 23
4
ALISON CECILY FINGER
25 Sep 23
4
KEVIN F MCLAUGHLIN
25 Sep 23
4
Laurence Reid
25 Sep 23
4
Matthew C Kapusta
25 Sep 23
4
Sara Nochur
25 Sep 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 40.74 mm | 40.74 mm | 40.74 mm | 40.74 mm | 40.74 mm | 40.74 mm |
| Cash burn (monthly) | (no burn) | 1.40 mm | 6.35 mm | 5.50 mm | 3.42 mm | 4.07 mm |
| Cash used (since last report) | n/a | 22.76 mm | 103.34 mm | 89.54 mm | 55.73 mm | 66.22 mm |
| Cash remaining | n/a | 17.98 mm | -62.60 mm | -48.81 mm | -14.99 mm | -25.48 mm |
| Runway (months of cash) | n/a | 12.9 | -9.9 | -8.9 | -4.4 | -6.3 |
Institutional ownership, Q2 2023
88.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 37 |
| Opened positions | 3 |
| Closed positions | 6 |
| Increased positions | 5 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 55.80 bn |
| Total shares | 22.23 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Orbimed Advisors | 4.95 mm | $19.04 bn |
| Third Rock Ventures III | 3.14 mm | $0.00 |
| TRV GP Iii | 3.14 mm | $12.09 bn |
| REGN Regeneron Pharmaceuticals | 2.10 mm | $9.75 mm |
| BLK BlackRock | 1.81 mm | $6.97 bn |
| GOOG Alphabet | 1.64 mm | $6.30 bn |
| GV 2016 | 1.64 mm | $0.00 |
| Samsara BioCapital | 801.63 k | $3.09 bn |
| Vanguard | 642.33 k | $2.47 bn |
| Bessemer | 494.07 k | $1.90 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Sep 23 | Sara Nochur | Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,000 | 0.00 | 0 |
| 25 Sep 23 | Sara Nochur | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.2 | 20,000 | 124.00 k | 0 |
| 25 Sep 23 | Sara Nochur | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.78 | 5,000 | 23.90 k | 0 |
| 25 Sep 23 | Sara Nochur | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.3 | 10,000 | 23.00 k | 0 |
| 25 Sep 23 | Matthew C Kapusta | Common Stock | Sale back to company | Dispose D | No | No | 0 | 10,000 | 0.00 | 0 |
| 25 Sep 23 | Matthew C Kapusta | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.34 | 10,000 | 33.40 k | 0 |
| 25 Sep 23 | Laurence Reid | Common Stock | Sale back to company | Dispose D | No | No | 0 | 220,849 | 0.00 | 0 |
| 25 Sep 23 | Laurence Reid | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.4 | 1,072,539 | 4.72 mm | 0 |
| 25 Sep 23 | Laurence Reid | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.73 | 72,000 | 268.56 k | 0 |
| 25 Sep 23 | Laurence Reid | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.5 | 187,500 | 656.25 k | 0 |